Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
USRE37650E1 · kind E1 · reissue
59Cited by
13References
5Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 2, 2000 |
| Grant date | Apr 9, 2002 |
| Priority date | — |
| Expiry date | Feb 2, 2020 |
Classification
- Technology area (CPC —)General
Abstract
This invention relates to the treatment of intimation in a patient suffering from such disorder. More specifically, the invention relates to mono- and/or bicyclic aryl or heteroaryl quinazoline compounds in the treatment of inflammation.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.